Sheet 1 of 1

Form PTO-1449

U.S. Department of Commerce

Date Filed: 12 November 2007

DOCKET NO. 61169.00040 (O-2863 CIP)	APPLN. NO. 10/812,292
APPLICANT: Discher et al.	
FILING DATE: March 29, 2004	GROUP: 1615

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes/No/Abstract

OTHER DOCUMENT(S) *(Including Author, Title, Date, Pertinent Pages, etc.)*

X		*Arcamone* F., Doxorubicin: Anticancer Antibiotics, Academic Press, New York, 1981.
2		*Hobbie R.K. et al.*, "Transport through neutral membranes," Intermediate Physics for Medicine and Biology, 3rd ed., AIP Press, New York, 114-124 (1997).
3		*Jellinek H.H.G.*, "Aspects of Degradation and Stabilization of Polymers," *Elsevier*, New York, 617-657 (1978).
4		*Lasic et al.*, "Medical Applications of Liposomes," Elsevier, New York, pp. 1-24 (1998).
5		*Li X. et al.*, "In Vitro Protein Release and Degradation of Poly-dl-lactide-poly(ethylene glycol) Microspheres with Entrapped Human Serum Albumin: Quantitative Evaluation of the Factors Involved in Protein Release Phases," *Pharmaceutical Research*, 18(1): 117-124.
6		*Pitt C.G.*, "Poly(e-caprolactone) and its copolymers," R. Langer and M. Chasin (Eds.), Biodegrabable Polymers as Drug Delivery Sytems, Marcel Dekker, New York, NY, pp. 71-120 (1990).
7		*Piskins et al.*, "Novel PDLLA/PEG copolymer micelles as drug carriers," J. Biomaterials Science, Polymer Ed. 7:359-373 (1995).
8		*Shah et al.*, "Poly-DL-lactic acid: polyethylene glycol block copolymers. The influence of polyethylene glycol on the degradation of poly-DL-lactic acid," *Biomaterials Science*, Polymer Ed. 5:421-431 (1994).
9		*Szleifer et al.*, "Curvature Elasticity of Pure and Mixed Surfactant Films," Phys. Rev. Lett. 60(19):1966 (1988).

Examiner Signature: _____ **Date Considered:** 1/2/08

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

PTO-1449.doc

PTO/SB/08A (09-06)
Approved for use through 03/31/2007. OMB 0651-003
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/812,292
				Filing Date	March 29, 2004
				First Named Inventor	Discher et al.
(Use as many sheets as necessary)				**Group Art Unit**	1615
				Examiner Name	Eric E. Silverman
Sheet	1	of		**Attorney Docket Number**	61169.00040 (O-2863 CIP)

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Pantentee or Applicant of Cited Document	Papers, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.[1]	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		Country Code[3] Number[4] - Kind Code[5] (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS (cont'd.)		
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	
EEA	*Adlakha-Hutcheon G. et al.*, "Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity," *Nature Biotechnology*, 17:775-779 (1999).	
2	*Ahmed F. et al.*, "Block Copolymer Assemblies with Cross-Link Stabilization: From Single-Component Monolayers to Bilayer Blends with PEO – PLA," *Langmuir*, 19:6505-6511(2003).	
3	*Allen C. et al.*, "*Polycaprolactone-b-poly(ethylene oxide) copolymer micelles as a delivery vehicle for dihydrotestosterone,*" *Journal of Controlled Release*, 63:275-286.	
4	*Anderson et al.*, "Biodegradation and biocompatibility of PLA and PLGA microsphere," *Advanced Drug Delivery Reviews*, 28:5-24 (1997).	
5	*Angelova M.I. et al.*, "Preparation of giant vesicles by external AC electric fields. Kinetics and applications," *Prog. Coll. Polym. Sci.*, 89:127-131 (1992).	
6	*Araki H. et al.*, "Antitumor Effect of Cisplatin Incorporated into Polyactic Acid Microcapsules," *Artificial* Organs, 23(2):161-168 (1999).	
EEA	*Arcamone* F., Doxorubicin: Anticancer Antibiotics, Academic Press, New York, 1981.	
8	*Avgoustakis et al.*, "PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties," *J. of Controlled Release*, 79:123-135 (2002).	
9	*Bates F. et al.*, "Polymer-Polymer Phase Behavior," *Science*, 251:898-905 (1991).	
10	*Bates F. et al.*, "Block Copolymers – Designer Soft Materials," *Physics Today*, 32-38 (1999).	
EEA	*Belbella A. et al.*, "In vitro degradation of nanospheres from poly(D,L-lactides) of different molecular weights and polydispersities," *International Journal of Pharmaceutics*, 129:95-102 (1996).	

12	*Ben-Shaul A.*, Molecular Theory of Chain Packing, Elasticity and Lipid-Protein Interaction in Lipid Bilayers, in *Handbook of Biological Physics*, Vol. 1, chapter 7, Elsevier Science, Amsterdam, 1995.	
13	*Bergstrand N. et al.*, "Interactions between pH-sensitive liposomes and model membranes," Biophysical Chemistry, 104:361-379 (2003).	
14	*Bermudez H. et al.*, "Molecular Weight Dependence of Polymersome Membrane Structure, Elasticity, and Stability," *Macromolecules*, 35:8203-8208 (2002).	
15	*Boomer J.A. et al.*, "Acid –Triggered Release from Sterically Stabilized Fusogenic Liposomes via a Hydrolytic DePEGylation Strategy," *Langmuir*, 19:6408-6415 (2003).	
16	*Boomer J. et al.*, "Synthesis of acid-labile diplasmenyl lipids for drug and gene delivery applications," *Chemistry and Physics of Lipids*, 99:145-153 (1999).	
17	Brunner A. et al., "pH and Osmotic Pressure Inside Biodegradable Microspheres During Erosion," *Pharmaceutical Research*, 16(6):847-853 (1999).	
18	*Bu Z. et al.*, "Diffusion of Dextran in Aqueous (Hydroxypropyl) cellulose," *Macromolecules*, 27:1187-1194 (1994).	
19	*Cevic & Lasic*, "Material Transport Across Permeability Barriers by Means of Lipid Vesicles," in Handbook of Biological Physics, chaps. 9-10 (1995).	
20	*Chaieb S. et al.*, "Spontaneous curvature-induced," *Physical Review E.*, 58(6):7733-7737 (1998).	
21	*Chawla J. et al*, "Biodegradable poly(ε-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen," *International Journal of Pharmaceutics*, 249:127-138 (2002).	
22	*Chécot F. et al.*, "From supramolecular polymersome to stimuli-responsive nano-capsules based on poly (diene-b-peptide) diblock copolymer," The European Physical Journal E, 10:25-35 (2003).	
23	*Cornelissen J. et al.*, "Helical superstructures from charged poly (styrene)-poly (isocyanodipeptide) block cipolymers," *Science*, 280:1427 (1998).	
24	*Dalhaimer P. et al.*, "Synthetic cell elements from block copolymers-hydrodynamic aspects," *C.R. Physique*, 4:251-258 (2003).	
25	*Davidsen et al.*, "Secreted phospholipase A_2 as a new enzymatic trigger mechanism for localized liposomal drug release and absorption in diseased tissue," Biochim. Biophys. Acta 1609:95-101 (2003).	
26	*Deuling H. J. et al.*, "The Curvature Elasticity of Fluid Membranes: A Catalogue Of Vesicle Shapes," *Le Journal De Physique*, 37:1335-1345 (1976).	
27	*Dimova R. et al*, "Hyperviscous diblock copolymer vesicles," The European Physical Journal E., 7:241-250 (2002).	
28	*Ding J. et al.*, "Water-Soluble Hollow Nanospheres as Potential Drug Carriers," *J. Phys. Chem B.*, 102:6107-6113 (1998).	
29	*Discher B. et al.*, "Cross-linked Polymersome Membranes: Vesicles with Broadly Adjustable Properties," *J. Phys. Chem. B*, 106:2848-2854.	
30	*Discher B. et al.*, "Polymersomes: Tough Vesicles Made from Diblock Copolymer," *Science*, 284(5417):1143-1146 (1999).	
31	*Discher D. E. et al.*, "Polymer Vesicles: Review," Science, 297(5583):967 (2002).	
32	*Discher D. E. et al.*, "Molecular Maps of Red Cell Deformation: Hidden Elasticity and in Situ Connectivity," *Science*, 266(5187):1032-1035 (1994).	
33	*Döbereiner H.G. et al.*, "Mapping vesicle shapes into the phase diagram: A comparison of experiment and theory," *Physical Review E.*, 55(4):4458-4474 (1997).	
34	*Evans E. et al.*, "Entropy-Driven Tension and Bending Elasticity in condensed-Fluid Membranes," *Phys. Rev. Lett.*,. 64(17):2094-2097 (1990).	
35	*Evans E. et al.*, "Physical Properties of Surfactant Bilayer Membranes: Thermal Transitions, Elasticity, Rigidity, Cohesion, and Colloidal Interactions," J. Physical Chemistry, 91:4219-4228 (1987).	
36	*Fendler J. H.*, "Polymerized surfactant vesicles: novel membrane mimetic systems," Science, 223:888 (1984).	
37	*Gerasimov O.V. et al*, "Acid-catalyzed plasmenylcholine hydrolysis and its effect on bilayer permeability: a quantitative study," *Biochim. Biophys.*, 1324:200-214 (1997).	

38	*Govender T. et al.*, "Defining the drug incorporation properties of PLA-PEG nanoparticles," *Internat'l J. Pharmaceutics*, 199:95-110 (2000).	
39	*Gref R. et al.*, "Biodegradable long-circulating polymeric nanosphere," Science, 263(5153):1600-1603 (1994).	
40	*Guo X. et al.*, "Mechanism of pH-Triggered Collapse of Phosphatidylethanolamine Liposomes Stabilized by an Ortho Ester Polyethyleneglycol Lipid," *Biophysical Journal*, 84:1784-1795 (2003).	
41	*Hagan S.A. et al.*, "Polyactide-Poly (ethylene glycol) Copolymers as Drug Delivery Systems. 1. Characterization of Water Dispersible Micelle-Forming System," *Langmuir*, 12:2153-2161 (1996).	
42	*Hajduk D. A. et al.*, "Complex Phase Behavior in Aqueous Solutions of Poly (ethylene oxide) – Poly (ethylethylene) Block Copolymers," J. Phys. Chem., 102:4269-4276 (1998).	
43	*Harasym T. O. et al.*, "Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidyicholine/cholesterol liposome," Cancer Chemother Pharmacol., 40:309-317 (1997).	
44	*Haran G. et al.*, "Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases," *Biochi,. Biophys. Acta*, 1151:201-215 (1993).	
45	*Helfrich W. et al.*, "Undulations, Steric Interaction and Cohesion of Fluid Membranes (*)," *Nuovo* Cimento, 3D(1):137-151 (1984).	
46	*Henselwood F. et al.*, "Water-Soluble Porous Nanospheres," *Macromolecules*, 31:4213-4217 (1998).	
47	*Hentze et al.*, "Lyotropic Mesophases of Poly (ethylene oxide)-*b*-poly(butadiene) Diblock Copolymers and Their Cross-Linking to Generate Ordered Gels," *Macromolecules*, 32:5803-5809 (1999).	
48	*Hillmyer M.A. et al.*, "Synthesis and Characterization of Model Polyalkane – Poly (ethylene oxide) Block Copolymers," *Macromolecules*, 29:6994-7002 (1996).	
49	*Hillmyer M. A.*, "Complex Phase Behavior in Solvent-Free Nonionic Surfactants," *Science*, 271:976-978 (1996).	
50	*Hobbie R.K. et al.*, "Transport through neutral membranes," Intermediate Physics for Medicine and Biology, 3rd ed., AIP Press, New York, 114-124 (1997).	
51	*Holland et al.*, "Poly(ethylene glycol)-Lipid conjugates Promote Bilayer Formation in Mixtures of Non-Bilayer-Forming Lipids," *Biochemistry*, 35:2610-2617 (1996).	
52	*Hrkach J. S. et al.*, "Nanotechnology for biomaterials engineering: structural characterization of amphiphilic polymeric nanoparticles by ^{1}H NMR spectroscopy," *Biomaterials*, 18:27-30 (1997).	
53	*Israelachvili*, in Intermolecular and Surface Forces, 2nd ed., Pt3 (Academic Press, New York) (1995).	
54	*Jain S. et al.*, "On the Origins of Morphological Complexity in Block Copolymer Surfactants," *Science*, 300:460-464 (2003).	
55	*Jellinek H.H.G.*, "Aspects of Degradation and Stabilization of Polymers," *Elsevier*, New York, 617-657 (1978).	
56	*Jiang et al.*, "Stabilization and Controlled Release of Bovine Serum Albumin Encapsulated in Poly(D, L-lactide) and Poly(ethylene glycol) Microsphere Blends," *Pharmaceutical Research*, 18(6):878-885 (2001).	
57	*Jørgensen K. et al.*, "Biophysical mechanisms of phospholipase A2 activation and their use in liposome-based drug deliver," *FEBS Letters*, 531:23-27 (2002).	
58	*Kidane A. et al.*, "Surface modification of polyethylene terephthalate using PEO-polybutadiene-PEO triblock copolymers," Colloids and Surfaces B: Biointerfaces, 18:347-353 (2000).	
59	*Kim H. et al.*, "Surface Stabilization of Diblock PEG-PLGA Micelles by Polymerization of N-Vinyl-2pyrrolidone," *Macromol. Rapid Commun.*, 23:26-31 (2002).	
60	*Kim J. et al.*, "Core-stabilized Polymeric Micelle as Potential Drug Carrier: Increased Solubilization of Taxol," *Polymers for Advanced Technologies*, 10:647-654 (1999).	
61	*Kirpotin D. et al.*, "Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol)," *FEBS Lett.*, 388:115-118 (1996).	
62	*Klibanov A. L. et al.*, "Ambphipathic polyethyleneglycols effectively prolong the circulation time of liposomes," *FEBS Lett.* 268(1):235-237 (1990).	
63	*Kong G. et al.*, "Efficacy of Liposomes and Hyperthermia in a Human Tumor Xenograft Model: Importance of triggered Drug Release," *Cancer Research* 60:6950-6957 (2000).	
64	*Koltover I. et al.*, "An Inverted Hexagonal Phase of Cationic Liposome – DNA Complexes Related to DNA Release and Delivery," *Science*, 281:78-81 (1998).	
65	*Kostanski J. W. et al.*, "Preparation, Characterization, and In Vitro Evaluation of 1- and 4-Month Controlled Release Orntide PLA and PLAGA Microspheres," *Pharmaceutical Development and* Technology, 5(4):585-596 (2000).	

66	*Kukula H. et al.*, "The Formation of Polymer Vesicles or "Peptosomes" by Polybutadiene-block-poly (L-glutamates)s in Dilute Aqueous Solution," *J. Amer. Chem. Soc.* 124(8):1658-1663 (2002).	
67	*Kweon H. et al.*, "A novel degradable polycaprolactone networks for tissue engineering," *Biomaterial*, 24:801-808 (2003).	
68	*Ladavière C. et al.*, "Slow Reorganization of Small Phosphatidylcholine Vesicles upon Adsorption of Amphilic Polymers," *Journal of Colloid and Interface Science*, 241:178-187 (2001).	
69	*Ladavière C. et al.*, "Lateral Organization of Lipid Membranes Induced by Amphiphilic Polymer Inclusions," *Langmuir*, 18-7320-7327 (2002).	
70	*Lasic D.D. et al.*, "Medical Applications of Liposomes," *Elsevier*, Amsterdam, New York, 1-16(1998).	
71	*Lee J. et al.*, "Preparation, Stability, and In Vitro Performance of Vesicles Made with Diblock Copolymers," *Biotechnology and Bioengineering*, 73(2):135-145 (2001).	
72	*Li X. et al.*, "In Vitro Degradation and Release Profiles of Poly-DL-Lactide-Poly (ethylene glycol) Microspheres with Entrapped Proteins," *Journal of Applied Polymer Science*, 78:140-148 (2000).	
73	*Li X. et al.*, "In Vitro Protein Release and Degradation of Poly-dl-lactide-poly(ethylene glycol) Microspheres with Entrapped Human Serum Albumin: Quantitative Evaluation of the Factors Involved in Protein Release Phases," *Pharmaceutical Research*, 18(1): 117-124.	
74	*Lin Z. et al.*, "Vesicle Formation in Electrolyte Solutions of a New Cationic Siloxane Surfactant," *J. Phys. Chem.*, 97:3571-3578 (1993).	
75	*Lin Z. et al.*, "Cryogenic Electron Microscopy of Rodlike or Wormlike Micelles in Aqueous Solutions of Nonionic Surfactant Hexaethylene Glycol Monohexadecyl Ether," *Langmuir*, 8:2200-2205 (1992).	
76	*Liu D. et al.*, "Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonin," *Biochim. Biophys. Acta. Biomembranes*, 1235:140-146 (1995).	
77	*Liu G. et al.*, "Polystyrene-block-polyisoprene Nanofiber Fractions. 2 Viscometric Study," *Macromolecules*, 36:2049-2054 (2003).	
78	*Longo M. et al.*, "Interaction of the Influenza Hemagglutinin Fusion Peptide with Lipid Bilayers: Area Expansion and Permeation," *Biophysical Journal*, 73:1430-1439 (1997).	
79	*Lucke A. et al.*, "Biodegradable poly(D,L-lactic acid)-poly(ethylene glycol)-monomethyl ether diblock copolymers: structures and surface properties relevant to their use as biomaterials," *Biomaterials*, 21:2361-2370 (2000).	
80	*Matsumoto J. et al.*, "Preparation of nanoparticles consisted of poly(L-lactide)-poly(ethylene glycol) – poly (L-lactide) and their evualuation in vitro," *International J. of Pharmaceutics*, 185:93-101 (1999).	
81	*Meng F. et al., "Biodegradable Polymersomes," Macromolecules, 36:3004-3006 (2003).*	
82	*Morita T. et al.*, "Applicability of various amphiphilic polymers to the modification of protein release kinetics from biodegradable reservoir-type microspheres," *European Journal of Pharmaceutics and Biopharmaceutics*, 51:45-53 (2001).	
83	*Mueller A. et al.*, "Light-Stimulated Destabilzation of Peg-Liposomes," *Polymer Preprints* (ACS), 40(2):205 (1999).	
84	*Najafi F. et al.*, "Biodegradable micelles/polymersomes from fumaric/sebacic acids and poly(ethylene glycol)," *Science*, 24:1175-1182 (2003).	
85	*Nardin C. et al.*, "Polymerized ABA Triblock Copolymer Vesicles," *Langmuir*, 16:1035-1041 (2000).	
86	*Needham D. et al.*, "Elastic deformation and failure of lipid bilayer membranes containing cholesterol," *Biophys. J.*, 58:997-1009 (1990).	
87	*Needham D. et al.*, in Vesicles, M. Rosoff, Ed. (Dedder, New York, 1996), chap. 9.	
88	*Needham D. et al.*, "The developmenet and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors," Advanced Drug Delivery Reviews, 53:285-305 (2001).	
89	*Netz R. et al.*, "Pore formation and rupture in fluid bilayers," *Physical Review E.*, 53(4):3875-3885.	
90	*Panagi Z. et al.*, "Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles," *International Journal of Pharmaceutics*, 221:143-152 (2001).	
91	*Pitt C.G.*, "Poly(e-caprolactone) and its copolymers," R. Langer and M. Chasin (Eds.), Biodegrabable Polymers as Drug Delivery Sytems, Marcel Dekker, New York, NY, pp. 71-120 (1990).	
92	*Penco M. et al.*," Degradation behavior of block copolymers containing poly(lactic-glycolic acid) and poly(ethylene glycol segments," *Biomaterials*, 17(16):1583-1590 (1996).	
93	*Peracchia M. T. et al.*, "PEG-coated nanospheres from amphiphilic diblock and multiblock copolymers: Investiation of their drug encapsulation and release characteristics," *Journal of Controlled Release*, 46:223-231 (1997).	
94	*Petrov A. G. et al.*, "Elastic and Flexoelectic Aspects of Out-Of-Plane Fluctuations in Biological and	

	Model Membranes," *Prog. In Surf. Science*, 16:389-512 (1984).	
95	*Photos P.J. et al.*, "Polymer vesicles in vivo: correlations with PEG molecular weight," *Journal of Controlled Release*, 90:323-334 (2003).	
96	*Piskins et al.*, "Novel PDLLA/PEG copolymer micelles as drug carriers," J. Biomaterials Science, Polymer Ed. 7:359-373 (1995).	
97	*Riley et al.*," Physicochemical Evaluation of Nanoparticles Assembled from Poly(lactic acid)-Poly(ethylene glycol) (PLA-PEG) Block Copolymers as Drug Delivery Vehicles," *Langmuir*, 17:3168-3174 (2001).	
98	*Rui Yuanjin et al.*, "Diplasmenylcholine-Folate Liposomes: An Efficient Vehicle for Intracellular Drug Delivery," *Journal of the American Chemical Society*, 120(44):11213-11218 (1998).	
99	*Roux D. et al.*," Curvature Elasticity of Pure and Mixed Surfactant Films," *Physical Review Letters*, 60(19):1966-1969 (1988).	
100	*Salem A. K. et al.*, "Synthesis and Characterisation of a Degradable Poly(lactic acid) – Poly(ethylene glycol) Copolymer with Biotinylated End Groups," *Biomacromolecules*, 2:575-580 (2001).	
101	*Savic R. et al.*, "Micellar Nanocontainers Distribute to Defined Cytoplasmic Organelles," *Science*, 300:615-618 (2003).	
102	*Schillén K. et al.*, "Vesicles Formed from a Poly(ethylene oxide)-Poly(propylene oxide0-Poly(ethylene oxide) Triblock Copolymer in Dilute Aqueous Solution," *Macromolecules*, 32:6885-6888 (1999).	
103	*Schmitt et al.*, "Importance of Distinct Water Environments in the Hydrolysis of Poly(DL-lactife-co-glycolide)," *Macromolecules*, 27:743-748(1994).	
104	*Seifert U. et al.*, "Shape transformations of vesicles: Phase diagram for spontaneous-curvature and bilayer-coupling models," *Physical Review A.*, 44(2):1182-1202 (1991).	
105	*Sisson T. et al.*, "Cross-Linking Polymerizations in Two-Dimensional Assemblies," *Macromolecules*, 29:8321-8329 (1996).	
106	*Shah et al.*, "Poly-DL-lactic acid: polyethylene glycol block copolymers. The influence of polyethylene glycol on the degradation of poly-DL-lactic acid," *Biomaterials Science*, Polymer Ed. 5:421-431 (1994).	
107	*Shin J. et al.*, "Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids," *Journal of Controlled Release*, 91:187-200 (2003).	
108	*Svetina S. et al.*, "Membrane bending energy and shape determination of phospholipids vesicles and red blood cells," *Eur. Biophys. J.*, 17:101-111(1989).	
109	*Szleifer et al.*, "Curvature Elasticity of Pure and Mixed Surfactant Films," Phys. Rev. Lett. 60(19):1966 (1988).	
110	*Tseng Y. et al.*, "Grafting of ethylene glycol-butadiene block copolymers onto dimethyl-dichlorosilane-coated glass by γ-irradiation," *Biomaterials*, 16:963-972 (1995).	
111	*Ulbrich K. et al.*, "HPMA copolymers with pH-controlled release of doxorubicin In vitro cytotoxicity and in vivo antitumor activity," *Journal of Controlled Release*, 87:33-47 (2003).	
112	*Valentini M. et al.*, "Precise Determination of the Hydrophobic/Hydrophilic Junction in Polymeric Vesicles," *Langmuir*, 19:4852-4855 (2003).	
113	*Warriner H. et al.*, "Lamellar biogels: fluid-membrane-based hydrogels containing polymer lipids," *Science*, 271(5251):969-973 (1996).	
114	*Woo B. et al.*, "Preparation, charazterization and in vivo evaluation of 120-day poly(D,L-lactide) leuprolide microspheres," Journal of Controlled Release, 75:307-315 (2001).	
115	*Won Y. et al.*, "Giant Wormlike Rubber Micelles," *Science*, 283:960-963 (1999).	
116	*Wymer N. et al.*, "Cascade Liposomal Triggering: Light-Induced Ca^{2+} Release from Diplasmenylcholine Liposomes Triggers PLA_2-Catalyzed Hydrolysis and Contents Leakage from DDP Liposomes," Bioconjugate Chem., 9(3): 305-308 (1998).	
117	*Yasugi K. et al.* , "Sugar-Installed Polymer Micelles: Synthesis and Micellization of Poly(ehty glycol) – poly(D,L-lactide) Block Copolymers Having Sugar Groups at the PEG Chain End," Macromolecules, 32:8024-8032 (1999).	
118	*Yu K. et al.*, "Bilayer Morphologies of Self-Assembled Crew-Cut Aggregates of Amphiphilic PS-*b*-PEO Diblock Copolymers in Solution,' Macromolecules, 31:3509-3518 (1998).	
119	*Zalipshy S. et al.*, "New Detachable Poly(ethylene glycol) conjugates: Cysteine-Cleavable Lipopolymers Regenerating Natural Phospholipid, Diacyl Phosphatidylethanolamine," Bioconjugate Chemistry, 10:703-707 (1999).	
120	*Zhigaltsev I. et al.*, "Triggered release of doxorubicin following mixing of cationic and anionic liposomes," Biochim. Biophys. Acta. 1565:129-135 (2002).	

Examiner Signature		Date Considered	1/2/08

EXAIMER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of his form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issues the document, by the two-letter code (WIPO Standard ST 3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16, if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR1.136(a). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 6 minutes to complete, including gathering and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.ad